United States
NASA's Management of Reimbursable Agreements
The Office of Inspector General examined NASA’s management of more than $2 billion in annual reimbursable agreements under which NASA agrees to provide domestic and international partners goods, services, or facilities the Agency is not fully utilizing.
Audit of NASA’s Information Technology Supply Chain Risk Management Efforts
The Office of Inspector General evaluated the effectiveness of NASA’s supply chain risk management efforts to protect the confidentiality, integrity, and availability of NASA data, computer systems, and networks.
Audit of NASA's Security Operations Cener
The Office of Inspector General assessed NASA’s management of the Security Operations Center (SOC) located at Ames Research Center, which responds to Agency-wide security threats to NASA networks and IT systems.
NASA’s Compliance with the Improper Payments Information Act for Fiscal Year 2017
The Office of Inspector General evaluated the Agency’s fiscal year 2017 compliance with the Improper Payments Information Act.
Audit of Commercial Resupply Services to the International Space Station
The Office of Inspector General evaluated NASA’s management of its commercial cargo contracts under which private companies transport supplies, equipment, and experiments to the International Space Station.
NASA's Management of GISS: The Goddard Institute for Space Studies
The Office of Inspector General assessed NASA's management of GISS (located in New York City) and its prominent role in Earth science research and the development of global climate models.
Review of NASA's Purchase and Travel Card Programs
The Office of Inspector General examined NASA’s internal controls to guard against fraud and misuse by employees in its purchase and travel card programs.
NASA's Compliance with Federal Export Control Laws
Audit of the National Space Biomedical Research Institute
The Office of Inspector General examined NASA’s management of its 20‐year,$484 million cooperative agreement with the NSBRI to advance the Agency’sbiomedical research efforts.